Halozyme Therapeutics (HALO) Tops Q4 EPS by 11c, provides guidance
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $98.66 -2%
Financial Fact:
Interest and other income, net: 334K
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Interest and other income, net: 334K
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $1.26, $0.11 better than the analyst estimate of $1.15. Revenue for the quarter came in at $298 million versus the consensus estimate of $294.15 million.
GUIDANCE:
Halozyme Therapeutics sees FY2025 EPS of $4.95-$5.35, versus the consensus of $5.05. Halozyme Therapeutics sees FY2025 revenue of $1.15-1.225 billion, versus the consensus of $1.184 billion.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Movano (MOVE) Misses Q2 EPS by 195c
- Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
- JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
